Daré Bioscience CEO to Highlight Women's Health Innovation at BIO 2026
Event summary
- Daré Bioscience CEO Sabrina Martucci Johnson to participate in multiple speaking engagements at BIO International Convention 2026, June 22-25 in San Diego.
- Johnson will deliver a corporate presentation on June 23, discussing strategy, portfolio, and milestones.
- Company will highlight its focus on closing gaps in women's health, including contraception, menopause, and vaginal health.
- Investors and attendees can request meetings with Daré management during the convention.
The big picture
Daré Bioscience is positioning itself as a leader in women's health innovation at a time when the sector is gaining increased attention but still faces significant funding and regulatory challenges. The company's participation in BIO 2026 underscores its commitment to addressing unmet needs in areas like contraception, menopause, and vaginal health, where historical underinvestment has left gaps in care. The strategic focus on these areas could pay off as awareness and demand for solutions grow.
What we're watching
- Market Positioning
- How Daré's focus on women's health will differentiate it in a crowded biotech landscape.
- Investor Interest
- Whether the company's participation in BIO 2026 will attract new strategic partners or investors.
- Regulatory Progress
- The pace at which Daré can advance its pipeline through clinical development and regulatory approvals.
Related topics